
Avalyn Pharma rose 2.7% from $29.49 to $30.28, behind the S&P 500's +5.0%. Its worst day was May 18 (−10.8%), and its low came Oct 19 at $23.33.
Apr 30, 2026 – Nov 13, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Avalyn Pharma shares fell 10.8%, while the S&P 500 fell 0.1%.
−10.8%, the year's worst day · S&P 500 −0.1%
EPS of $-21.83 missed the $-16.38 estimate on $0.00 revenue.
+2.6% · S&P 500 −0.7%
Story events cover the past 12 months · Times ET
Avalyn Pharma shares rose 10.2%, while the S&P 500 fell 1.0%.
+10.2%, the year's best day · S&P 500 −1.0%
EPS of $-0.98 missed the $-0.66 estimate on $0.00 revenue.
+5.4% · S&P 500 +0.3%
Avalyn Pharma closed at its lowest level of the year, 20.9% below where the year started.
−1.4% · S&P 500 +0.4%
EPS of $-0.67 beat the $-0.73 estimate on $0.00 revenue.
−3.3% · S&P 500 −0.4%
Where it ended: a close of $30.28 on Nov 13, 2026. Up next: Q4 2026 earnings on Feb 5, 2027 (EPS est. $-0.71).
Nothing in the past 12 months.
All AVLN dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for AVLN and SPY from Benzinga historical bars. Not investment advice.